PMC:7033706 / 2773-3065 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"47","span":{"begin":222,"end":223},"obj":"Gene"},{"id":"55","span":{"begin":212,"end":221},"obj":"Species"}],"attributes":[{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Gene:43740568"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"SP, signal peptide; NTD, N-terminal domain; RBD, receptor-binding domain; FP, fusion peptide, HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane domain; CP, cytoplasmic domain. (C) The target sites in 2019-nCoV S for development of vaccines, antibodies and fusion/entry inhibitors."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":168,"end":179},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma66835"}],"text":"SP, signal peptide; NTD, N-terminal domain; RBD, receptor-binding domain; FP, fusion peptide, HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane domain; CP, cytoplasmic domain. (C) The target sites in 2019-nCoV S for development of vaccines, antibodies and fusion/entry inhibitors."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":20,"end":23},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0008449"},{"id":"A9","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0018075"}],"text":"SP, signal peptide; NTD, N-terminal domain; RBD, receptor-binding domain; FP, fusion peptide, HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane domain; CP, cytoplasmic domain. (C) The target sites in 2019-nCoV S for development of vaccines, antibodies and fusion/entry inhibitors."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T32","span":{"begin":4,"end":10},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T33","span":{"begin":11,"end":18},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T34","span":{"begin":85,"end":92},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T35","span":{"begin":164,"end":166},"obj":"http://purl.obolibrary.org/obo/PR_000005794"}],"text":"SP, signal peptide; NTD, N-terminal domain; RBD, receptor-binding domain; FP, fusion peptide, HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane domain; CP, cytoplasmic domain. (C) The target sites in 2019-nCoV S for development of vaccines, antibodies and fusion/entry inhibitors."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":0,"end":2},"obj":"Chemical"},{"id":"T10","span":{"begin":11,"end":18},"obj":"Chemical"},{"id":"T11","span":{"begin":74,"end":76},"obj":"Chemical"},{"id":"T12","span":{"begin":85,"end":92},"obj":"Chemical"},{"id":"T13","span":{"begin":138,"end":140},"obj":"Chemical"},{"id":"T15","span":{"begin":164,"end":166},"obj":"Chemical"},{"id":"T17","span":{"begin":281,"end":291},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_74820"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_74750"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_55460"},{"id":"A14","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_74861"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_3380"},{"id":"A16","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_73461"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"SP, signal peptide; NTD, N-terminal domain; RBD, receptor-binding domain; FP, fusion peptide, HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane domain; CP, cytoplasmic domain. (C) The target sites in 2019-nCoV S for development of vaccines, antibodies and fusion/entry inhibitors."}

{"project":"LitCovid-sentences","denotations":[{"id":"T19","span":{"begin":0,"end":292},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"SP, signal peptide; NTD, N-terminal domain; RBD, receptor-binding domain; FP, fusion peptide, HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane domain; CP, cytoplasmic domain. (C) The target sites in 2019-nCoV S for development of vaccines, antibodies and fusion/entry inhibitors."}